WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

• Cowen 43^rd Annual Healthcare Conference
  Forum: Fireside Chat
  Date: Monday, March 6, 2023
  Time: 9:10 a.m. ET

• Guggenheim 4^th Annual Healthy Altitudes Summit
  Forum: Fireside Chat
  Date: Wednesday, March 15, 2023
  Time: 9:00 a.m. ET

A webcast and subsequent archived replay of each fireside chat, when available, may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of posterior segment uveitis, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:
Anne Marie Fields
Stern IR
Direct: 332-213-1956
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Amy Phillips
Green Room Communications
Direct: 412-327-9499
This email address is being protected from spambots. You need JavaScript enabled to view it.